{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T05:27:52Z","timestamp":1774934872270,"version":"3.50.1"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T00:00:00Z","timestamp":1639353600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Asymptomatic or symptomatic infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can be followed by reinfection. The protection conferred by prior infection among coronavirus disease 2019 (COVID-19) patients is unclear. We assessed the incidence of SARS-CoV-2 reinfection and the protection effect of previous infection against reinfection.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We searched PubMed, EMBASE, Cochrane, Scopus, Web of Science, and ClinicalTrials.gov for publications up until the end date of May 1, 2021. The reinfection rate of recovered patients and the protection against reinfection were analyzed using meta-analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Overall, 19 studies of 1096 reinfection patients were included. The pooled reinfection rate was 0.65% (95% confidence interval [CI] 0.39\u20130.98%). The symptomatic reinfection rate was a bit lower (0.37% [95%\u200aCI 0.11\u20130.78%], <jats:italic toggle=\"yes\">I<\/jats:italic>\n                                 <jats:sup>2<\/jats:sup>\u200a=\u200a99%). The reinfection rate was much higher in high-risk populations (1.59% [95%\u200aCI 0.30\u20133.88%], <jats:italic toggle=\"yes\">I<\/jats:italic>\n                                 <jats:sup>2<\/jats:sup>\u200a=\u200a90%). The protection against reinfection and symptomatic reinfection was similar (87.02% [95%\u200aCI 83.22\u201389.96%] and 87.17% [95%\u200aCI 83.09\u201390.26%], respectively).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The rate of reinfection with SARS-CoV-2 is relatively low. The protection against SARS-CoV-2 after natural infection is comparable to that estimated for vaccine efficacy. These data may help guide public health measures and vaccination strategies in response to the COVID-19 pandemic. High-quality clinical studies are needed to establish the relevant risk factors in recovered patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cm9.0000000000001892","type":"journal-article","created":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T14:02:40Z","timestamp":1639576960000},"page":"145-152","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":44,"title":["Reinfection rates among patients previously infected by SARS-CoV-2: systematic review and meta-analysis"],"prefix":"10.1097","volume":"135","author":[{"given":"Yinjun","family":"Mao","sequence":"first","affiliation":[{"name":"Department of Pharmacy, First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian 350005, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiwei","family":"Wang","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Mental Disorders and Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing 100088, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Ma","sequence":"additional","affiliation":[{"name":"Institute of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanshan","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, National Clinical Research Center for Digestive Disease, Beijing Digestive Disease Center, Beijing Key Laboratory for Precancerous Lesion of Digestive Disease, Beijing, 100050, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Centre, Beijing 100191, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,1,20]]},"reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ijsu.2020.04.018","article-title":"The socio-economic implications of the coronavirus pandemic (COVID-19): a review","volume":"78","author":"Nicola","year":"2020","journal-title":"Int J Surg"},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"e13423","DOI":"10.1111\/eci.13423","article-title":"Global perspective of COVID-19 epidemiology for a full-cycle pandemic","volume":"50","author":"Ioannidis","year":"2020","journal-title":"Eur J Clin Invest"},{"key":"R4-20250603","first-page":"ciaa1275","article-title":"COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing","author":"To","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/cid\/ciaa1330","article-title":"Symptomatic SARS-CoV-2 reinfection by a phylogenetically distinct strain","volume":"73","author":"Van Elslande","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R6-20250603","first-page":"ciaa1451","article-title":"Asymptomatic reinfection in two healthcare workers from India with genetically distinct SARS-CoV-2","author":"Gupta","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S1473-3099(20)30764-7","article-title":"Genomic evidence for reinfection with SARS-CoV-2: a case study","volume":"21","author":"Tillett","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"e335","DOI":"10.1016\/S2468-2667(21)00055-4","article-title":"Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study","volume":"6","author":"Graham","year":"2021","journal-title":"Lancet Public Health"},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/jrsm.12","article-title":"A basic introduction to fixed-effect and random-effects models for meta-analysis","volume":"1","author":"Borenstein","year":"2010","journal-title":"Res Synth Methods"},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/jech-2013-203104","article-title":"Meta-analysis of prevalence","volume":"67","author":"Barendregt","year":"2013","journal-title":"J Epidemiol Community Health"},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1467-985X.2008.00552.x","article-title":"A re-evaluation of random-effects meta-analysis","volume":"172","author":"Higgins","year":"2009","journal-title":"J R Stat Soc Ser A Stat Soc"},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"2100092","DOI":"10.2807\/1560-7917.ES.2021.26.5.2100092","article-title":"Antibodies to SARS-CoV-2 protect against re-infection during outbreaks in care homes, September and October 2020","volume":"26","author":"Jeffery-Smith","year":"2021","journal-title":"Euro Surveill"},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMoa2034545","article-title":"Antibody status and incidence of SARS-CoV-2 infection in health care workers","volume":"384","author":"Lumley","year":"2021","journal-title":"N Engl J Med"},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(21)00575-4","article-title":"Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study","volume":"397","author":"Hansen","year":"2021","journal-title":"Lancet"},{"key":"R23-20250603","first-page":"ciaa1846","article-title":"Assessment of the risk of SARS-CoV-2 reinfection in an intense re-exposure setting","author":"Abu-Raddad","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R24-20250603","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1001\/jamainternmed.2021.0366","article-title":"Association of SARS-CoV-2 seropositive antibody test with risk of future infection","volume":"181","author":"Harvey","year":"2021","journal-title":"JAMA Intern Med"},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1017\/S095026882100087X","article-title":"COVID-19 reinfection in Shahroud, Iran: a follow up Study","volume":"149","author":"Zare","year":"2021","journal-title":"Epidemiol Infect"},{"key":"R26-20250603","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ijid.2021.02.115","article-title":"Main differences between the first and second waves of COVID-19 in Madrid, Spain","volume":"105","author":"Soriano","year":"2021","journal-title":"Int J InfectDis"},{"key":"R27-20250603","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.jinf.2021.01.005","article-title":"Prior COVID-19 significantly reduces the risk of subsequent infection, but reinfections are seen after eight months","volume":"82","author":"Breathnach","year":"2021","journal-title":"J Infect"},{"key":"R28-20250603","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/j.jinf.2020.12.023","article-title":"Prior SARS-CoV-2 infection is associated with protection against symptomatic reinfection","volume":"82","author":"Hanrath","year":"2021","journal-title":"J Infect"},{"key":"R29-20250603","first-page":"ciab234","article-title":"Reinfection rates among patients who previously tested positive for COVID-19: a Retrospective Cohort Study","author":"Sheehan","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R30-20250603","first-page":"ciab345","article-title":"Re-infection with SARS-CoV-2 in patients undergoing serial laboratory testing","author":"Qureshi","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R31-20250603","doi-asserted-by":"crossref","first-page":"100331","DOI":"10.1016\/j.ajogmf.2021.100331","article-title":"Repeat positive severe acute respiratory syndrome coronavirus 2 (coronavirus disease 2019) testing \u226590 days apart in pregnant women","volume":"3","author":"Dubelbeiss","year":"2021","journal-title":"Am J Obstet Gynecol MFM"},{"key":"R32-20250603","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.3390\/jcm10091968","article-title":"Risk of SARS-CoV-2 infection in previously infected and non-infected cohorts of health workers at high risk of exposure","volume":"10","author":"Sanchez-Montalva","year":"2021","journal-title":"J Clin Med"},{"key":"R33-20250603","doi-asserted-by":"crossref","first-page":"100861","DOI":"10.1016\/j.eclinm.2021.100861","article-title":"SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy","volume":"35","author":"Abu-Raddad","year":"2021","journal-title":"EClinicalMedicine"},{"key":"R34-20250603","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S0140-6736(21)00675-9","article-title":"SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN)","volume":"397","author":"Hall","year":"2021","journal-title":"Lancet"},{"key":"R35-20250603","doi-asserted-by":"crossref","first-page":"e13520","DOI":"10.1111\/eci.13520","article-title":"SARS-CoV-2 re-infection risk in Austria","volume":"51","author":"Pilz","year":"2021","journal-title":"Eur J Clin Invest"},{"key":"R36-20250603","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1017\/S0950268821000662","article-title":"SARS-CoV-2 re-infection: development of an epidemiological definition from India","volume":"149","author":"Mukherjee","year":"2021","journal-title":"Epidemiol Infect"},{"key":"R37-20250603","doi-asserted-by":"crossref","first-page":"273","DOI":"10.15585\/mmwr.mm7008a3","article-title":"Suspected recurrent SARS-CoV-2 infections among residents of a skilled nursing facility during a second COVID-19 outbreak - Kentucky, July-November 2020","volume":"70","author":"Cavanaugh","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R38-20250603","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1126\/science.abd7728","article-title":"Robust neutralizing antibodies to SARS-CoV-2 infection persist for months","volume":"370","author":"Wajnberg","year":"2020","journal-title":"Science"},{"key":"R39-20250603","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1093\/cid\/ciaa344","article-title":"Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019","volume":"71","author":"Zhao","year":"2020","journal-title":"Clin Infect Dis"},{"key":"R40-20250603","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S1473-3099(20)30783-0","article-title":"What reinfections mean for COVID-19","volume":"21","author":"Iwasaki","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"R41-20250603","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.cmi.2020.11.002","article-title":"Nucleic acid amplification tests on respiratory samples for the diagnosis of coronavirus infections: a systematic review and meta-analysis","volume":"27","author":"Hellou","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"R42-20250603","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1002\/jmv.26648","article-title":"Systematic review and meta-analysis of factors associated with re-positive viral RNA after recovery from COVID-19","volume":"93","author":"Hoang","year":"2021","journal-title":"J Med Virol"},{"key":"R43-20250603","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.rce.2020.06.012","article-title":"Recurrent positive SARS-CoV-2 RNA tests in recovered and discharged patients","volume":"220","author":"Ulhaq","year":"2020","journal-title":"Rev Clin Esp"},{"key":"R44-20250603","first-page":"e2020014","article-title":"SARS-CoV-2 recurrent RNA positivity after recovering from coronavirus disease 2019 (COVID-19): a meta-analysis","volume":"91","author":"Mattiuzzi","year":"2020","journal-title":"Acta Biomed"},{"key":"R45-20250603","doi-asserted-by":"crossref","first-page":"100839","DOI":"10.1016\/j.eclinm.2021.100839","article-title":"A systematic review and meta-analysis of discharged COVID-19 patients retesting positive for RT-PCR","volume":"34","author":"Ren","year":"2021","journal-title":"EClinicalMedicine"},{"key":"R46-20250603","doi-asserted-by":"crossref","first-page":"20692","DOI":"10.1038\/s41598-020-77739-y","article-title":"Recurrent SARS-CoV-2 RNA positivity after COVID-19: a systematic review and meta-analysis","volume":"10","author":"Azam","year":"2020","journal-title":"Sci Rep"},{"key":"R47-20250603","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000001892","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T19:04:56Z","timestamp":1748977496000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000001892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,13]]},"references-count":43,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000001892","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,13]]}}}